Uniqure NVNASDAQ:QURE
- LAST PRICE5.9400
- TODAY'S CHANGE (%)0.1600 (2.7682%)
- Bid / Lots5.9300/ 1
- Ask / Lots5.9400/ 2
- Open / Previous Close5.8700 / 5.7800
- Day Range
- 52 Week Range
- Volume337,268
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 11750 | 5.8996 |
| 09:33 ET | 2369 | 5.91 |
| 09:35 ET | 1025 | 5.99 |
| 09:37 ET | 3500 | 5.98 |
| 09:39 ET | 500 | 6.01 |
| 09:42 ET | 5100 | 6.0552 |
| 09:44 ET | 14624 | 6.035 |
| 09:48 ET | 1460 | 6.0401 |
| 09:50 ET | 2998 | 6.03 |
| 09:51 ET | 800 | 6.03 |
| 09:53 ET | 1627 | 6.04 |
| 09:55 ET | 550 | 5.999 |
| 09:57 ET | 3165 | 5.9367 |
| 10:00 ET | 300 | 5.97 |
| 10:02 ET | 300 | 5.95 |
| 10:04 ET | 477 | 5.98 |
| 10:06 ET | 193 | 5.96 |
| 10:08 ET | 416 | 5.98 |
| 10:11 ET | 100 | 6 |
| 10:13 ET | 200 | 5.995 |
| 10:15 ET | 700 | 5.95 |
| 10:18 ET | 951 | 5.95 |
| 10:20 ET | 100 | 5.95 |
| 10:22 ET | 3815 | 6.05 |
| 10:24 ET | 5043 | 6.095 |
| 10:26 ET | 8215 | 6.12 |
| 10:29 ET | 900 | 6.135 |
| 10:31 ET | 200 | 6.13 |
| 10:33 ET | 5465 | 6.12 |
| 10:36 ET | 1565 | 6.12 |
| 10:38 ET | 1802 | 6.13 |
| 10:40 ET | 2165 | 6.13 |
| 10:42 ET | 380 | 6.11 |
| 10:44 ET | 600 | 6.11 |
| 10:45 ET | 1525 | 6.09 |
| 10:47 ET | 800 | 6.11 |
| 10:49 ET | 2094 | 6.13 |
| 10:51 ET | 350 | 6.15 |
| 10:54 ET | 100 | 6.145 |
| 10:58 ET | 400 | 6.13 |
| 11:00 ET | 1758 | 6.12 |
| 11:02 ET | 400 | 6.12 |
| 11:03 ET | 1345 | 6.12 |
| 11:05 ET | 800 | 6.1287 |
| 11:07 ET | 300 | 6.11 |
| 11:09 ET | 4565 | 6.141 |
| 11:12 ET | 500 | 6.14 |
| 11:14 ET | 1630 | 6.18 |
| 11:16 ET | 5176 | 6.21 |
| 11:18 ET | 450 | 6.22 |
| 11:20 ET | 1265 | 6.227 |
| 11:21 ET | 1331 | 6.2 |
| 11:23 ET | 800 | 6.2 |
| 11:25 ET | 700 | 6.22 |
| 11:27 ET | 800 | 6.2 |
| 11:30 ET | 1886 | 6.21 |
| 11:32 ET | 1733 | 6.21 |
| 11:34 ET | 2333 | 6.235 |
| 11:36 ET | 1182 | 6.225 |
| 11:38 ET | 1500 | 6.21 |
| 11:39 ET | 1882 | 6.16 |
| 11:41 ET | 1000 | 6.17 |
| 11:43 ET | 900 | 6.19 |
| 11:45 ET | 700 | 6.17 |
| 11:48 ET | 900 | 6.15 |
| 11:50 ET | 1877 | 6.17 |
| 11:52 ET | 700 | 6.15 |
| 11:54 ET | 1600 | 6.18 |
| 11:56 ET | 1200 | 6.15 |
| 11:57 ET | 900 | 6.16 |
| 11:59 ET | 800 | 6.15 |
| 12:01 ET | 1241 | 6.15 |
| 12:03 ET | 3316 | 6.16 |
| 12:06 ET | 869 | 6.14 |
| 12:08 ET | 1000 | 6.15 |
| 12:10 ET | 2453 | 6.13 |
| 12:12 ET | 900 | 6.13 |
| 12:14 ET | 900 | 6.11 |
| 12:15 ET | 5595 | 6.0701 |
| 12:17 ET | 1433 | 6.09 |
| 12:19 ET | 1100 | 6.06 |
| 12:21 ET | 800 | 6.07 |
| 12:24 ET | 3400 | 6.045 |
| 12:26 ET | 1214 | 6.02 |
| 12:28 ET | 2015 | 6.05 |
| 12:30 ET | 1900 | 6.035 |
| 12:32 ET | 1200 | 6.025 |
| 12:33 ET | 2245 | 6.0224 |
| 12:35 ET | 1018 | 6.025 |
| 12:37 ET | 2383 | 6.025 |
| 12:39 ET | 3073 | 6.04 |
| 12:42 ET | 1130 | 6.03 |
| 12:44 ET | 900 | 6.03 |
| 12:46 ET | 800 | 6.02 |
| 12:48 ET | 600 | 6.03 |
| 12:50 ET | 15758 | 6 |
| 12:51 ET | 2013 | 5.99 |
| 12:53 ET | 5797 | 6.01 |
| 12:55 ET | 1100 | 6 |
| 12:57 ET | 500 | 6 |
| 01:00 ET | 1200 | 6.01 |
| 01:02 ET | 4636 | 6.01 |
| 01:04 ET | 500 | 5.99 |
| 01:06 ET | 1250 | 6 |
| 01:08 ET | 800 | 5.99 |
| 01:09 ET | 500 | 5.98 |
| 01:11 ET | 800 | 5.99 |
| 01:13 ET | 2200 | 6.01 |
| 01:15 ET | 1861 | 6.02 |
| 01:18 ET | 1333 | 5.99 |
| 01:20 ET | 1587 | 5.97 |
| 01:22 ET | 789 | 5.97 |
| 01:24 ET | 2513 | 5.97 |
| 01:26 ET | 3518 | 5.98 |
| 01:27 ET | 2485 | 5.98 |
| 01:29 ET | 300 | 5.98 |
| 01:31 ET | 850 | 5.99 |
| 01:33 ET | 2216 | 6 |
| 01:36 ET | 400 | 6.01 |
| 01:38 ET | 2886 | 6.0178 |
| 01:40 ET | 1955 | 6 |
| 01:42 ET | 1191 | 6.01 |
| 01:44 ET | 655 | 6 |
| 01:45 ET | 400 | 6 |
| 01:47 ET | 1400 | 5.995 |
| 01:49 ET | 1000 | 6 |
| 01:51 ET | 760 | 5.98 |
| 01:54 ET | 400 | 5.98 |
| 01:56 ET | 850 | 5.98 |
| 01:58 ET | 1096 | 5.975 |
| 02:00 ET | 1100 | 6 |
| 02:02 ET | 200 | 5.99 |
| 02:03 ET | 1800 | 6.01 |
| 02:05 ET | 3595 | 6 |
| 02:07 ET | 1531 | 6.01 |
| 02:09 ET | 812 | 6 |
| 02:12 ET | 2250 | 6 |
| 02:14 ET | 600 | 6.01 |
| 02:16 ET | 921 | 5.99 |
| 02:18 ET | 500 | 5.99 |
| 02:20 ET | 748 | 5.97 |
| 02:21 ET | 800 | 5.98 |
| 02:23 ET | 5300 | 5.99 |
| 02:25 ET | 400 | 5.98 |
| 02:27 ET | 400 | 6 |
| 02:30 ET | 300 | 5.99 |
| 02:32 ET | 1200 | 6 |
| 02:34 ET | 493 | 5.99 |
| 02:36 ET | 500 | 5.99 |
| 02:38 ET | 1926 | 5.955 |
| 02:39 ET | 900 | 5.95 |
| 02:41 ET | 891 | 5.95 |
| 02:43 ET | 4000 | 5.94 |
| 02:45 ET | 200 | 5.94 |
Nov 21, 2024
Nov 6, 2024
DJ uniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co., from 2:04PM ET on Wednesday Nov 06, 2024 by Dow Jones
2:04PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Is Maintained at Neutral by Goldman Sachs, from 12:40PM ET on Wednesday Nov 06, 2024 by Dow Jones
12:40PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Is Maintained at Outperform by RBC Capital, from 12:22PM ET on Wednesday Nov 06, 2024 by Dow Jones
12:22PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Price Target Maintained With a $28.00/Share by Cantor Fitzgerald, from 9:52AM ET on Wednesday Nov 06, 2024 by Dow Jones
9:52AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 281.7M | -1.2x | --- |
Iteos Therapeutics Inc | 303.9M | -2.7x | --- |
C4 Therapeutics Inc | 300.0M | -2.6x | --- |
Absci Corp | 290.7M | -3.0x | --- |
Ocugen Inc | 264.3M | -5.1x | --- |
Molecular Partners AG | 219.0M | -2.8x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Technical Operations Officer
- Amin Abujoub
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $281.7M |
|---|---|
Revenue (TTM) | $28.6M |
Shares Outstanding | 48.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-4.96 |
Book Value | $4.34 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 9.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -700.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
